Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer

Fu Tsai Chung, Kang Yun Lee, Chih Wei Wang, Chih Chen Heh, Yao Fei Chan, Huan Wu Chen, Chih Hsi Kuo, Po Hao Feng, Ting Yu Lin, Chun Hua Wang, Chun Liang Chou, Hao Cheng Chen, Shu Min Lin, Han Pin Kuo

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Our study investigated whether tumor-associated macrophages (TAMs) in advanced non-small cell lung cancer (NSCLC) are related to treatment response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and may be a predictor of survival. Of 206 advanced NSCLC patients treated (first-line) with an EGFR-TKI at the study hospital from 2006 to 2009, 107 with adequate specimens for assessing CD68 immunohistochemistry as a marker of TAMs were assessed. After EGFR-TKI treatment, response was observed in 55 (51%) patients, and the median follow-up period was 13.5 months. Most TAMs were located in the tumor stroma (>95%) and positively costained with the M2 marker CD163. TAM counts were significantly higher in patients with progressive disease than in those without (p <0.0001), a trend that remained in patients with known EGFR mutation status (n = 59) and those with wild-type EGFR (n = 20). High TAM counts, among other factors (e.g., wild-type EGFR), were significantly related to poor progression-free survival (PFS) and overall survival (OS) (all p <0.0001 for TAMs). Multivariate Cox analyses showed that high TAM counts and EGFR mutations were both independent factors associated with PFS [odds ratio (OR), 8.0; 95% confidence interval (CI), 2.87-22.4; p = 0.0001 and OR, 0.03; 95% CI, 0.003-0.31; p = 0.003, respectively] and OS (OR, 2.641; 95% CI, 1.08-6.5; p = 0.03 and OR, 0.14; 95% CI, 0.03-0.56; p = 0.006, respectively). TAMs are related to treatment response irrespective of EGFR mutation and can independently predict survival in advanced NSCLC treated with an EGFR-TKI.

Original languageEnglish
JournalInternational Journal of Cancer
Volume131
Issue number3
DOIs
Publication statusPublished - Aug 1 2012
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Macrophages
Neoplasms
Odds Ratio
Confidence Intervals
Survival
Mutation
Disease-Free Survival
Tumor Biomarkers
Therapeutics
Multivariate Analysis
Immunohistochemistry

Keywords

  • advanced NSCLC
  • EGFR-TKIs
  • outcome
  • response
  • TAM

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. / Chung, Fu Tsai; Lee, Kang Yun; Wang, Chih Wei; Heh, Chih Chen; Chan, Yao Fei; Chen, Huan Wu; Kuo, Chih Hsi; Feng, Po Hao; Lin, Ting Yu; Wang, Chun Hua; Chou, Chun Liang; Chen, Hao Cheng; Lin, Shu Min; Kuo, Han Pin.

In: International Journal of Cancer, Vol. 131, No. 3, 01.08.2012.

Research output: Contribution to journalArticle

Chung, Fu Tsai ; Lee, Kang Yun ; Wang, Chih Wei ; Heh, Chih Chen ; Chan, Yao Fei ; Chen, Huan Wu ; Kuo, Chih Hsi ; Feng, Po Hao ; Lin, Ting Yu ; Wang, Chun Hua ; Chou, Chun Liang ; Chen, Hao Cheng ; Lin, Shu Min ; Kuo, Han Pin. / Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. In: International Journal of Cancer. 2012 ; Vol. 131, No. 3.
@article{f04b0810971b425b82a34db9b93e7a15,
title = "Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer",
abstract = "Our study investigated whether tumor-associated macrophages (TAMs) in advanced non-small cell lung cancer (NSCLC) are related to treatment response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and may be a predictor of survival. Of 206 advanced NSCLC patients treated (first-line) with an EGFR-TKI at the study hospital from 2006 to 2009, 107 with adequate specimens for assessing CD68 immunohistochemistry as a marker of TAMs were assessed. After EGFR-TKI treatment, response was observed in 55 (51{\%}) patients, and the median follow-up period was 13.5 months. Most TAMs were located in the tumor stroma (>95{\%}) and positively costained with the M2 marker CD163. TAM counts were significantly higher in patients with progressive disease than in those without (p <0.0001), a trend that remained in patients with known EGFR mutation status (n = 59) and those with wild-type EGFR (n = 20). High TAM counts, among other factors (e.g., wild-type EGFR), were significantly related to poor progression-free survival (PFS) and overall survival (OS) (all p <0.0001 for TAMs). Multivariate Cox analyses showed that high TAM counts and EGFR mutations were both independent factors associated with PFS [odds ratio (OR), 8.0; 95{\%} confidence interval (CI), 2.87-22.4; p = 0.0001 and OR, 0.03; 95{\%} CI, 0.003-0.31; p = 0.003, respectively] and OS (OR, 2.641; 95{\%} CI, 1.08-6.5; p = 0.03 and OR, 0.14; 95{\%} CI, 0.03-0.56; p = 0.006, respectively). TAMs are related to treatment response irrespective of EGFR mutation and can independently predict survival in advanced NSCLC treated with an EGFR-TKI.",
keywords = "advanced NSCLC, EGFR-TKIs, outcome, response, TAM, advanced NSCLC, EGFR-TKIs, outcome, response, TAM",
author = "Chung, {Fu Tsai} and Lee, {Kang Yun} and Wang, {Chih Wei} and Heh, {Chih Chen} and Chan, {Yao Fei} and Chen, {Huan Wu} and Kuo, {Chih Hsi} and Feng, {Po Hao} and Lin, {Ting Yu} and Wang, {Chun Hua} and Chou, {Chun Liang} and Chen, {Hao Cheng} and Lin, {Shu Min} and Kuo, {Han Pin}",
year = "2012",
month = "8",
day = "1",
doi = "10.1002/ijc.27403",
language = "English",
volume = "131",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer

AU - Chung, Fu Tsai

AU - Lee, Kang Yun

AU - Wang, Chih Wei

AU - Heh, Chih Chen

AU - Chan, Yao Fei

AU - Chen, Huan Wu

AU - Kuo, Chih Hsi

AU - Feng, Po Hao

AU - Lin, Ting Yu

AU - Wang, Chun Hua

AU - Chou, Chun Liang

AU - Chen, Hao Cheng

AU - Lin, Shu Min

AU - Kuo, Han Pin

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Our study investigated whether tumor-associated macrophages (TAMs) in advanced non-small cell lung cancer (NSCLC) are related to treatment response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and may be a predictor of survival. Of 206 advanced NSCLC patients treated (first-line) with an EGFR-TKI at the study hospital from 2006 to 2009, 107 with adequate specimens for assessing CD68 immunohistochemistry as a marker of TAMs were assessed. After EGFR-TKI treatment, response was observed in 55 (51%) patients, and the median follow-up period was 13.5 months. Most TAMs were located in the tumor stroma (>95%) and positively costained with the M2 marker CD163. TAM counts were significantly higher in patients with progressive disease than in those without (p <0.0001), a trend that remained in patients with known EGFR mutation status (n = 59) and those with wild-type EGFR (n = 20). High TAM counts, among other factors (e.g., wild-type EGFR), were significantly related to poor progression-free survival (PFS) and overall survival (OS) (all p <0.0001 for TAMs). Multivariate Cox analyses showed that high TAM counts and EGFR mutations were both independent factors associated with PFS [odds ratio (OR), 8.0; 95% confidence interval (CI), 2.87-22.4; p = 0.0001 and OR, 0.03; 95% CI, 0.003-0.31; p = 0.003, respectively] and OS (OR, 2.641; 95% CI, 1.08-6.5; p = 0.03 and OR, 0.14; 95% CI, 0.03-0.56; p = 0.006, respectively). TAMs are related to treatment response irrespective of EGFR mutation and can independently predict survival in advanced NSCLC treated with an EGFR-TKI.

AB - Our study investigated whether tumor-associated macrophages (TAMs) in advanced non-small cell lung cancer (NSCLC) are related to treatment response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and may be a predictor of survival. Of 206 advanced NSCLC patients treated (first-line) with an EGFR-TKI at the study hospital from 2006 to 2009, 107 with adequate specimens for assessing CD68 immunohistochemistry as a marker of TAMs were assessed. After EGFR-TKI treatment, response was observed in 55 (51%) patients, and the median follow-up period was 13.5 months. Most TAMs were located in the tumor stroma (>95%) and positively costained with the M2 marker CD163. TAM counts were significantly higher in patients with progressive disease than in those without (p <0.0001), a trend that remained in patients with known EGFR mutation status (n = 59) and those with wild-type EGFR (n = 20). High TAM counts, among other factors (e.g., wild-type EGFR), were significantly related to poor progression-free survival (PFS) and overall survival (OS) (all p <0.0001 for TAMs). Multivariate Cox analyses showed that high TAM counts and EGFR mutations were both independent factors associated with PFS [odds ratio (OR), 8.0; 95% confidence interval (CI), 2.87-22.4; p = 0.0001 and OR, 0.03; 95% CI, 0.003-0.31; p = 0.003, respectively] and OS (OR, 2.641; 95% CI, 1.08-6.5; p = 0.03 and OR, 0.14; 95% CI, 0.03-0.56; p = 0.006, respectively). TAMs are related to treatment response irrespective of EGFR mutation and can independently predict survival in advanced NSCLC treated with an EGFR-TKI.

KW - advanced NSCLC

KW - EGFR-TKIs

KW - outcome

KW - response

KW - TAM

KW - advanced NSCLC

KW - EGFR-TKIs

KW - outcome

KW - response

KW - TAM

UR - http://www.scopus.com/inward/record.url?scp=84862811913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862811913&partnerID=8YFLogxK

U2 - 10.1002/ijc.27403

DO - 10.1002/ijc.27403

M3 - Article

C2 - 22174092

AN - SCOPUS:84862811913

VL - 131

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -